SPDYA encodes Speedy A (Spy1), a non-cyclin activator of cell cycle kinases that regulates the G1/S phase transition by binding and directly activating CDK1 and CDK2 1. Unlike canonical cyclins, SPDYA induces conformational changes in CDK2 that bypass the need for activation loop phosphorylation, enabling CDK2 activation while rendering the kinase resistant to inhibition by tumor suppressors such as p27 2. During meiosis, SPDYA plays a critical role beyond cell cycle control: it interacts directly with the LINC complex component SUN1 to promote telomere-led chromosome 2 and homologous chromosome 2 during meiotic prophase I 3. SPDYA is also implicated in neural stem cell maintenance, with elevated expression in aggressive brain cancers including glioblastoma 4. In breast cancer, SPDYA promotes resistance to tamoxifen by activating ERK1/2 in a MEK-independent manner, increasing ligand-independent estrogen receptor α activation 5. Aberrant SPDYA methylation occurs in hepatocellular carcinoma across multiple etiologies and may serve as a biomarker 6. The gene's dual role in governing proliferation and meiotic progression, combined with its expression in multiple cancer types, positions SPDYA as a potential therapeutic target in oncology.